Mortality in <scp>US</scp> Veterans With Rheumatoid Arthritis Treated With Immune Checkpoint Inhibitors
Patients with RA who received ICIs for the treatment of malignancy did not experience increased mortality or differences in cause of death compared with patients without RA receiving ICIs. These preliminary data suggest ICI therapy may be considered as part of cancer treatment in RA patients based on individual patient circumstances.
Authors
- Tawnie Braaten (ORCID: https://orcid.org/0000-0002-9121-8958)
- Punyasha Roul
- Gary A. Kunkel
- Jessica A. Walsh (ORCID: https://orcid.org/0000-0002-4563-0845)
- Shardool Patel (ORCID: https://orcid.org/0000-0002-0274-8800)
- Brian C. Sauer (ORCID: https://orcid.org/0000-0002-3546-3051)
- Ted R. Mikuls (ORCID: https://orcid.org/0000-0002-0897-2272)
- Bryant R. England (ORCID: https://orcid.org/0000-0002-9649-3588)
- Maria OʼSullivan (ORCID: https://orcid.org/0000-0002-1152-979X)
- Grant W. Cannon (ORCID: https://orcid.org/0000-0001-6640-9173)
- Joshua F. Baker (ORCID: https://orcid.org/0000-0003-0170-028X)
- Jorge Rojas
Institutions
- University of Utah (US)
- VA Salt Lake City Healthcare System (US)
- VA Puget Sound Health Care System (US)
- Philadelphia VA Medical Center (US)
- VA Nebraska Western Iowa Health Care System (US)
- University of Nebraska Medical Center (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Arthritis Care & Research
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1002/acr.25691
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- U.S. Department of Veterans Affairs
- Rheumatology Research Foundation
- National Institutes of Health